TAK
タケダ・ファーマシューティカルズ
TAK
タケダ・ファーマシューティカルズ
Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Takeda Pharmaceuticals (TAK) remains a hold, with shares near 52-week highs and uncertainty about a major successor to Entyvio. TAK's Q1 showed 10% revenue growth, but bottom-line weakness from higher